-
27-07-2024, 12:03 PM
#21411
Member
Originally Posted by pierre
I believe that 45 days notice is given before any finalised change comes into force.
Ah yes, you are correct. Doctors and Medicare users could then work with a disclaimer that any tests needs to be submitted and reimbursed within 45 days. I'm not sure how long PEBs tests take or how the reimbursement process works, but that might work.
It is still heavy burden of uncertainty.
-
27-07-2024, 12:25 PM
#21412
Given the botch up of all sorts by Novitas and the uncertainty surrounding it, PEB should take them to court. It’s quite unfair for all the stakeholders to be kept in limbo.
Last edited by carrom74; 27-07-2024 at 12:28 PM.
Reason: Typo
-
27-07-2024, 01:39 PM
#21413
Member
Thoughts on how the market reads this on Monday?
-
27-07-2024, 01:51 PM
#21414
Member
I think PEB may need to provide a update on the extension provided by CMS to the market as the extension is new information technically. If PEB come out strong and says this is positive news, which while bringing uncertainty, could also bring more time for research milestones to be met, then I think the market reacts positively.
Craigs, Forsyth and etc all modeled PEB with pricing of around 12c and comments that a negative coverage decision would have been made on or by 26 July 2024. PEB should use the opportunity to update the market and the investment houses. The consensus has always been that PEB just needs more time to get research across the line to keep coverage. This is technically more time but also carries a fair amount of uncertainty still (but still a more positive position than what shareholders were in before 26 July 2024).
If PEB push out a positive update, I think PEB goes up alittle further. Else it will trade flat around the current range.
It is possible that PEB may also need to indicate to the market that it is not clear whether they will maintain or not maintain coverage by the September catch up pending a decision from Novitas.
Last edited by snigmac; 27-07-2024 at 02:05 PM.
-
27-07-2024, 03:03 PM
#21415
Was checking other companies which are listed to see any announcements…(same issue with CMS)…PancraGEN”s parent company has no announcements made( even along the lines of what PEB has made) …
https://ir.interpace.com/press-releases
-
27-07-2024, 03:22 PM
#21416
Member
Originally Posted by carrom74
Was checking other companies which are listed to see any announcements…(same issue with CMS)…PancraGEN”s parent company has no announcements made( even along the lines of what PEB has made) …
https://ir.interpace.com/press-releases
Castle bioscience is also impacted to a degree was only up 9%.
-
27-07-2024, 05:31 PM
#21417
One may say that Novitas has one job to do and considering this is their 2nd swing at this and they have botched it up again, they are not doing that one job very well at all. Regardless, PEB and others are at their mercy it would appear. Here's a link to the LCD process as well as links to the various laws that apply here for anyone interested https://www.cms.gov/cms-guide-medical-technology-companies-and-other-interested-parties/coverage/local-coverage-determination-process-and-timeline with further info here https://www.cms.gov/Regulations-and-...s/pim83c13.pdf.
Perhaps PEB need to investigate other markets, far too stressful for shareholders with almost all their eggs in the USA basket. I wonder why the UK is essentially untapped by PEB?
-
27-07-2024, 09:02 PM
#21418
Member
Originally Posted by 850man
The biggest market and the one with the most money by far is the US, I don't think anything else comes close.
-
28-07-2024, 09:04 AM
#21419
Member
Originally Posted by Moneyman
Thoughts on how the market reads this on Monday?
if at all it will be irrational
too murky to read between these lines
I get the feeling Novitas are too understaffed to deal with the complexities - not just with PEB but the other companies affected with reimbursement decisions.
PEB may have been pushed down their priority list
-
28-07-2024, 05:41 PM
#21420
Member
Peb
Is Novitis a private company given the job of approving the products for LCD ?
Are the potentially on the hook for massive legal issues if the product is good but they can’t work to a time line ?
Am I reading it correct that as there’s “no specific” time for the update due to reviewing that we will keep receiving payments until it’s been determined?
I’m tempted to double down to bring down my horrific average cost closer to break even 🤧
Originally Posted by sunnysleeper11
if at all it will be irrational
too murky to read between these lines
I get the feeling Novitas are too understaffed to deal with the complexities - not just with PEB but the other companies affected with reimbursement decisions.
PEB may have been pushed down their priority list
Tags for this Thread
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
|
|
Bookmarks